Institutional Biosafety Committee (IBC)

All applications must be received by 2 p.m. on submission deadline date.

The IBC reviews and approves protocols for research and teaching laboratories involving the following materials:

• Recombinant/synthetic nucleic acid molecules, viral vectors, CRSPR/CAS9, ZFN, etc.
  • (Basically, anything that is genetically modified or used to create genetic modifications)
• Infectious agents that can cause disease in humans and/or has significant environmental or agricultural impacts.
• Specific toxins listed on the Federal Select Agent website as Permissible Toxins.
• Human materials, blood, tissue, other specimens used in research and not clinical diagnosis.
• Non-human primate materials from old world monkeys of the genus macaque /Macaca.
• Genetically-modified animals, whole plants, and insects, etc.
• Animals or animal specimens known to be reservoirs/vectors of zoonotic diseases.

2025 HGT IBC Meetings occur the 1st Wednesday of the month. Complete document submission is required by due date listed below to prepare the documents for IBC review. Incomplete submissions or delays in responding to requests for information will delay the review date of a submission.

Complete document submission includes:

• Clinical Trial Protocol
• Investigators Brochure
• Pharmacy Manual or equivalent

Please note that the HGT IBC is a fee for service Committee provided through a third-party contract and is registered with the NIH as our designated committee of review of HGT protocols. Review fees are charged to the Sponsor or designated department at UCI.

Please direct any questions about the HGT IBC meeting submission requirements to Casey Stark (cstark@sabaiglobal.com).